Home › GenDx Receives Canadian License for HLA Typing Software

GenDx Receives Canadian License for HLA Typing Software

Aug 24, 2017

NEW YORK (GenomeWeb) – Dutch genetic testing firm GenDx announced on Wednesday that it has received a medical device license from Canadian regulators for its NGSengine human leukocyte antigen (HLA) typing software.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12
Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

What's Popular?

In Regulatory News

  1. FDA, Industry Willing to Collaborate on Dx Regulation via Legislation Despite Differences

    Premium

  2. Health Canada Approves Two BCR-ABL Tests

  3. LabCorp, Sysmex, Diazyme, and Others Receive FDA Clearances for Assays, Diagnostic Systems in October

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.